医学部 総合医学第1講座

坂倉 建一

Sakakura Kenichi  (Kenichi Sakakura)

基本情報

所属
自治医科大学 附属さいたま医療センター心血管治療部 教授 (心血管治療部長)
(兼任)附属さいたま医療センター循環器内科 教授
学位
医学博士(自治医科大学)

研究者番号
20773310
J-GLOBAL ID
201501004058346154
Researcher ID
AAK-4564-2020
researchmap会員ID
B000247981

学歴

 1

論文

 300
  • Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Kei Yamamoto, Yoshimasa Tsurumaki, Takunori Tsukui, Yusuke Watanabe, Takaaki Mase, Masaru Seguchi, Taku Kasahara, Masashi Hatori, Shun Ishibashi, Hiroshi Wada, Yusuke Tamanaha, Kenshiro Arao, Norifumi Kubo, Hideo Fujita
    Cardiovascular intervention and therapeutics 2025年7月23日  
    Slow flow is the most common complication of rotational atherectomy (RA). Compared with long single sessions, short single sessions may reduce the incidence of slow flow just after RA. This study aimed to compare the incidence of slow flow just after RA between short single session and long single session strategies. This multicenter, 1:1 randomized clinical trial was conducted at 3 hospitals in Japan. The short single session strategy was defined as repeating short single sessions (up to 15 s) of RA, whereas the long single session strategy was defined as repeating long single sessions (20-30 s) until the burr crossed the target lesion. The primary outcome was slow flow just after RA, which was defined as [(initial TIMI-frame count before RA) × 1.1 minus (TIMI-frame count just after RA)] less than 0. During the study period, 266 patients were included in the final study population and were randomly assigned to the Short single session group (n = 132) or the long single session group (n = 134). The protocol adherence rate was equally high in both groups (Short single session: 98.5% versus long single session 94.8%, p = 0.172). The incidence of slow flow just after RA was similar between the 2 groups (short single session:14.4% versus long single session: 14.9%, p > 0.999). In conclusion, this randomized trial did not show a benefit of the short single session strategy compared with the long single session strategy in RA with respect to the prevention of slow flow (Unique identifier: UMIN000047231).
  • Hiroyuki Jinnouchi, Kenichi Sakakura, Hideo Fujita
    Expert review of cardiovascular therapy 2025年7月12日  
    INTRODUCTION: In-stent calcification is recognized as a significant contributor to unfavorable clinical outcomes. Understanding the various types and underlying mechanisms of in-stent calcification can help interventional operators to make decisions. AREAS COVERED: This review will describe the distinct types of in-stent calcification, which are categorized into in-stent smooth calcification and in-stent calcified nodule. The mechanisms and characteristics of in-stent smooth calcification and calcified nodule will be summarized. Given the differences between these two types, treatment approaches will be discussed. This review will focus on histopathology and intracoronary imaging. For the purpose of this review, evidence was gathered from electronic literature searches via PubMed, with a particular focus on primary evidence published in the last 5 years. EXPERT OPINION: Several treatment devices are available such as conventional balloon, modified balloon, atherectomy device and intravascular lithotripsy, etc. In-stent smooth calcification and calcified nodule might result in different clinical courses after repeated target lesion revascularization. Understanding the mechanisms with the various types of in-stent calcification may assist operators in selecting appropriate treatment strategies.
  • Kiriha Nanri, Kenichi Sakakura, Hideo Fujita
    Heart and vessels 2025年7月12日  
  • Kiriha Nanri, Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Kei Yamamoto, Takunori Tsukui, Masashi Hatori, Taku Kasahara, Yusuke Watanabe, Shun Ishibashi, Hiroko Hasegawa, Masaru Seguchi, Hideo Fujita
    Heart and vessels 2025年5月13日  
    The impact of mid-range (mr) ejection fraction (EF) on long-term clinical outcomes has been reported in patients with heart failure but remains unclear in patients with ST-segment elevation myocardial infarction (STEMI). The purpose of this study was to compare the long-term clinical outcomes among STEMI patients with preserved EF (pEF), mrEF, and reduced EF (rEF), and to evaluate the significance of mrEF as a prognostic factor for patients with STEMI. We included 705 patients with STEMI and divided them into rEF group (n = 155), mrEF group (n = 155), and pEF group (n = 395) according to the pre-discharge EF. The primary endpoint was the major adverse cardiovascular events (MACE), which were defined as the composite of all-cause death, re-admission for heart failure, and non-fatal myocardial infarction (MI). The median follow-up duration was 906 days (Q1:349.5-Q3:1479). The Kaplan-Meier curves showed that MACE and re-admission for heart failure were more frequently observed in the rEF group, followed by the mrEF group, and least in the pEF group (p < 0.001). The multivariate Cox hazard analysis revealed that mrEF as well as rEF were significantly associated with MACE after controlling for confounding factors [rEF: hazard ratio (HR) 2.333, 95% confidence interval (CI) 1.350-4.034, p = 0.002, mrEF:HR1.852, 95%CI 1.139-3.010, p = 0.013]. Mid-range EF as well as rEF was significantly associated with MACE and re-admission for heart failure in patients with STEMI. Our results suggest that mrEF is an important prognostic factor in patients with STEMI.
  • Soichiro Ban, Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Kei Yamamoto, Takunori Tsukui, Masashi Hatori, Taku Kasahara, Shun Ishibashi, Yusuke Watanabe, Masaru Seguchi, Hideo Fujita
    Journal of clinical medicine 14(9) 2025年5月4日  
    Background: Peripheral arterial disease (PAD) is associated with cardiovascular events in patients with acute myocardial infarction (AMI). However, there are limited reports regarding the association between PAD and bleeding events. In this study, we aimed to evaluate whether PAD is independently associated with an increased risk of major bleeding events, in addition to major adverse cardiovascular events (MACEs), in patients with AMI undergoing percutaneous coronary intervention (PCI). Methods: We included 1391 patients with AMI who underwent PCI and divided them into the PAD group (n = 210) and the non-PAD group (n = 1181). The primary endpoint was total bleeding events, defined as Bleeding Academic Research Consortium type 3/5. The secondary endpoint was MACE, defined as the composite of all-cause death, non-fatal myocardial infarction, and hospitalization for heart failure. Results: The median follow-up duration was 653 days. Total bleeding events were more frequently observed in the PAD group than in the non-PAD group (24.8% vs. 11.3%, p < 0.001). The multivariate Cox hazard analysis confirmed that PAD was significantly associated with total bleeding events (HR 1.509; 95% CI 1.056-2.156, p = 0.024) as well as MACEs (HR 2.152; 95% CI 1.510-3.066, p < 0.001) after controlling for confounding factors. Conclusions: PAD was independently associated with a higher risk of major bleeding and cardiovascular events in patients with AMI undergoing PCI. These findings suggest that PAD should be recognized as a critical factor in risk stratification for AMI and may affect individualized bleeding risk management strategies in patients with AMI.

MISC

 33

書籍等出版物

 1

共同研究・競争的資金等の研究課題

 2

学術貢献活動

 4